A Two Pharma Horse Race In Follow-On Biologics
Executive Summary
In the horse race to develop follow-on biologics, there are two companies vying for the pole position: Teva Pharmaceutical Industries Ltd. and Merck & Co. Inc. Even as other pharmaceutical companies weigh the merits of building FOB capabilities, these two companies are demonstrating their commitment not just with words but with cold, hard cash.You may also be interested in...
Your First Drug's Approved and Launched...Now What?
FDA new drug approvals are making a comeback, and a group of biopharma first-timers are leading the way. To understand the challenges they face in the transition from discovery to commercialization, IN VIVO looked at 50 companies spanning the past 10 years. Finally reaching the US market might be a biotech's defining moment, but for those who build to last, there could be more rewards beyond that first approval.
Your First Drug's Approved and Launched...Now What?
FDA new drug approvals are making a comeback, and a group of biopharma first-timers are leading the way. To understand the challenges they face in the transition from discovery to commercialization, IN VIVO looked at 50 companies spanning the past 10 years. Finally reaching the US market might be a biotech's defining moment, but for those who build to last, there could be more rewards beyond that first approval.
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports